EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieOpen Access · CC BY 4.0

DETOUR2 trial outcomes demonstrate clinical utility of percutaneous transmural bypass for the treatment of long segment, complex femoropopliteal disease

Sean P Lyden, Peter A Soukas, Ajanta De, Barry Tedder, Jonathan Bowman, Jihad A Mustapha, Ehrin J Armstrong, DETOUR2 Trial Investigators

Journal of Vascular Surgery · 2024-06 · 79 (6) · 1420-1427.e2

DOI: 10.1016/j.jvs.2024.02.004 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Vascular Surgery, 2024-06. Verfasst von Sean P Lyden und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH. Electronic address: lydens@ccf.org. Hauptthemen laut MEDLINE: Popliteal Artery, Femoral Artery, Peripheral Arterial Disease, Vascular Patency. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Percutaneous transmural arterial bypass (PTAB) using the DETOUR system aims to create a percutaneous, endovascular femoropopliteal bypass for the treatment of long segment, complex superficial femoral and proximal popliteal artery disease. The goal of the DETOUR2 study is to investigate the safety and effectiveness of the therapy in comparison with pre-established performance goals. METHODS: The DETOUR2 investigational device exemption study is a prospective, single-arm, multicenter, international trial of symptomatic peripheral arterial disease patients (Rutherford classes 3-5) undergoing the DETOUR procedure for long segment (>20 cm) superficial femoral artery disease. Prespecified end points included primary safety (composite of major adverse events) at 30 days, and effectiveness (primary patency defined as freedom from restenosis or clinically driven target lesion revascularization) at 1 year. RESULTS: We enrolled 202 patients at 32 sites with 200 treated with the DETOUR system. The mean lesion length was 32.7 cm, of which 96% were chronic total occlusions (CTO) and 70% were severely calcified. Technical success was achieved in 100% of treated patients. The primary safety end point was met with a 30-day freedom from major adverse event rate of 93.0%. The 1-year primary effectiveness end point was met with 72.1% primary patency at 12 months. Primary-assisted and secondary patency were 77.7% and 89.0%, respectively, at 12 months. The 12 month deep venous thrombosis incidence was 4.1% with no pulmonary emboli reported. Venous quality-of-life scores showed no significant changes from baseline. There was a Rutherford improvement of at least one class through 12 months in 97.2% of patients. The mean ankle-brachial index also improved from 0.61 to 0.95 during this period. There were marked improvements in quality-of-life and functional status measures. CONCLUSIONS: The DETOUR2 study met both the primary safety and effectiveness end points, demonstrating clinical usefulness of this novel therapeutic strategy in long femoropopliteal lesions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Popliteal ArteryFemoral ArteryPeripheral Arterial DiseaseVascular PatencyHumansMaleFemaleAgedProspective StudiesTime FactorsMiddle AgedTreatment OutcomeEndovascular ProceduresQuality of LifeRisk Factors

Stichwörter der Autor:innen

EndovascularFemoropopliteal diseaseLong lesionsLower extremity bypassPeripheral chronic total occlusions (CTO)

Autor:innen und Institutionen

  • Department of Vascular Surgery, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH. Electronic address: lydens@ccf.org.
  • The Miriam Hospital/Brown Medical School, Providence, RI.
  • El Camino Hospital, Mountain View, CA.
  • St Bernards Medical Center, Jonesboro, AR.
  • The Vascular Experts, Darien, CT.
  • Advanced Cardiac & Vascular Centers, Grand Rapids, Michigan.

Zitieren

APA

Lyden, S. P., Soukas, P. A., De, A., Tedder, B., Bowman, J., Mustapha, J. A., Armstrong, E. J., & DETOUR2 Trial Investigators (2024). DETOUR2 trial outcomes demonstrate clinical utility of percutaneous transmural bypass for the treatment of long segment, complex femoropopliteal disease. Journal of Vascular Surgery, 79(6), 1420-1427.e2. https://doi.org/10.1016/j.jvs.2024.02.004

Vancouver

Lyden SP, Soukas PA, De A, Tedder B, Bowman J, Mustapha JA, et al. DETOUR2 trial outcomes demonstrate clinical utility of percutaneous transmural bypass for the treatment of long segment, complex femoropopliteal disease. Journal of Vascular Surgery. 2024;79(6):1420-1427.e2. doi:10.1016/j.jvs.2024.02.004

BibTeX
@article{Lyden2024,
  author = {Lyden, Sean P and Soukas, Peter A and De, Ajanta and Tedder, Barry and Bowman, Jonathan and Mustapha, Jihad A and Armstrong, Ehrin J and DETOUR2 Trial Investigators, DETOUR2 Trial Investigators},
  title = {DETOUR2 trial outcomes demonstrate clinical utility of percutaneous transmural bypass for the treatment of long segment, complex femoropopliteal disease},
  journal = {Journal of Vascular Surgery},
  year = {2024},
  volume = {79},
  number = {6},
  pages = {1420--1427.e2},
  doi = {10.1016/j.jvs.2024.02.004}
}
Kostenlos starten →